Major Depressive Disorder Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Major Depressive Disorder Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Major Depressive Disorder Pipeline Report
- DelveInsight’s Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
- The leading companies working in the Major Depressive Disorder Market include GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
- Promising Major Depressive Disorder Pipeline Therapies in the various stages of development include Brexpiprazole, Desvenlafaxine Succinate Sustained-Release 10mg, Cariprazine, Antidepressant Therapy (ADT), and others.
- October 2023: Neumora Therapeutics Inc. announced a study of phase 3 clinical trials for NMRA 335140. This is a randomized, double blind, placebo controlled, multicenter study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA 335140 501).
- October 2023: Intra-Cellular Therapies Inc. announced a study of Phase 3 clinical trials of Lumateperone. This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Request a sample and discover the recent advances in Major Depressive Disorder Treatment Drugs @ Major Depressive Disorder Pipeline Report
In the Major Depressive Disorder pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Major Depressive Disorder clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Major Depressive Disorder Overview
Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of Major Depressive Disorder isn’t known. However, there are several factors that can increase the risk of developing the condition.
Find out more about Major Depressive Disorder Therapeutics Assessment @ Major Depressive Disorder Preclinical and Discovery Stage Products
Major Depressive Disorder Emerging Drugs Profile
- SAGE-217: Sage Therapeutics
- REL-1017: Relmada Therapeutics, Inc
- Seltorexant: Minerva Sciences
- SP-624: Sirtsei Pharmaceuticals, Inc.
- SPL026: Small Pharma
- PDC-1421: BioLite Inc
Major Depressive Disorder Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the Major Depressive Disorder therapies. The Major Depressive Disorder companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Preregistration include SAGE Therapeutics.
DelveInsight’s Major Depressive Disorder pipeline report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
Major Depressive Disorder Pipeline Products have been categorized under various Molecule types such as
- Specific Antibody
- Peptides
- Small molecule
- Gene therapy
Learn more about the emerging Major Depressive Disorder Pipeline Therapies @ Major Depressive Disorder Clinical Trials Assessment
Scope of the Major Depressive Disorder Pipeline Report
- Coverage- Global
- Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
- Major Depressive Disorder Pipeline Therapies- Brexpiprazole, Desvenlafaxine Succinate Sustained-Release 10mg, Cariprazine, Antidepressant Therapy (ADT), and others.
Dive deep into rich insights for new drugs for Major Depressive Disorder Treatment, Visit @ Major Depressive Disorder Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Major Depressive Disorder: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Major Depressive Disorder – DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- SAGE-217: Sage Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- SP-624: Sirtsei Pharmaceuticals, Inc.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- SPL026: Small Pharma
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Major Depressive Disorder Key Companies
- Major Depressive Disorder Key Products
- Major Depressive Disorder- Unmet Needs
- Major Depressive Disorder- Market Drivers and Barriers
- Major Depressive Disorder- Future Perspectives and Conclusion
- Major Depressive Disorder Analyst Views
- Major Depressive Disorder Key Companies
- Appendix
For further information on the Major Depressive Disorder Pipeline therapeutics, reach out to Major Depressive Disorder Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/major-depressive-disorder-market
){kind=link}